Table 3.
Clinical course and response of docetaxel and ramucirumab with or without prophylactic PEG‐G‐CSF
| Variables | With prophylactic PEG‐G‐CSF | Without prophylactic PEG‐G‐CSF | P |
|---|---|---|---|
| N = 29 | N = 4 | ||
| No. of cycles (range) | |||
| Docetaxel | 4 (1–12) | 5 (2–8) | 0.61 |
| Ramucirumab | 4 (1–12) | 4.5 (1–8) | 0.63 |
| Frequency of dose reduction (%) | |||
| Docetaxel | 10 (34.5%) | 3 (75%) | 0.27 |
| Ramucirumab | 0 | 0 | |
| Response | |||
| CR | 0 | 0 | |
| PR | 9 (31.0%) | 2 (50%) | |
| SD | 9 (31.0%) | 0 | |
| PD | 2 (6.9%) | 0 | |
| NE | 9 (31.0%) | 2 (50%) | |
| Overall response rate | 31.0% | 50% | 0.58 |
| Disease control rate | 62.0% | 50% | > 0.99 |
| No. of patients administered sequence therapy | 0.57 | ||
| Yes | 19 (65.5%) | 2 (50%) | |
| No | 8 (27.6%)a | 2 (50%) | |
a
Two patients were continuously administered docetaxel plus ramucirumab. CR, complete response; NE, not evaluable; PD, progressive disease; PEG‐G‐CSF, pegylated‐granulocyte‐colony stimulating factor; PR, partial response; SD, stable disease.